Financial results: Elixinol; Emyria; Epsilon; Avecho; Creso Pharma; AusCann; MGC Pharma; Botanix; Zelira by Martin Lane and Steve Jones March 1, 2023April 30, 2024 Elixinol Wellness reported a 2022 year-end loss of A$10.5m, a 38% improvement on the previous year, […]
Elixinol wins A$835k arbitration ruling in stoush with German operator by Steve Jones February 14, 2023April 30, 2024
Company news: Althea; Cann Group; Emyria; Neurotech; Bod Science; Elixinol; Creso Pharma; MGC Pharma by Steve Jones and Martin Lane January 31, 2023February 2, 2023
Company news: Emyria; Ananda Wellness; InhaleRx; Cann Global; HFA by Steve Jones September 28, 2022April 29, 2024
Financial results: Avecho; AusCann; Zelira; Elixinol; Cann Group; Incannex; Creso Pharma; Medlab; Rua Bioscience by Steve Jones and Martin Lane September 1, 2022April 29, 2024
Strategic review continues at Elixinol as management mull sale or merger by Steve Jones May 4, 2022April 29, 2024
Elixinol Wellness boss steps down with sale or merger still on the cards by Martin Lane March 28, 2022April 29, 2024
All options on the table for Elixinol as losses narrow by 50% by Martin Lane February 28, 2022April 29, 2024
